Journal
CANCER TREATMENT REVIEWS
Volume 41, Issue 5, Pages 391-400Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.03.008
Keywords
Ewing sarcoma; Targeted therapies
Categories
Funding
- NCATS Grant (Center for Clinical and Translational Sciences) [UL1 TR000371]
- MD Anderson Cancer Center Support Grant [P30 CA016672]
Ask authors/readers for more resources
The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available